TDCS to Improve Post-Stroke Cognitive Impairment
The investigators will conduct a randomized, double-blinded, sham-controlled trial of approximately 60 patients with minor stroke and post-stroke mild cognitive impairment (psMCI). Participants will be individually randomized on enrollment using a random number generator to treatment with anodal tDCS + computerized cog
| Condition(s) | Stroke, Stroke Sequelae, Cognitive Impairment |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The investigators will conduct a randomized, double-blinded, sham-controlled trial of approximately 60 patients with minor stroke and post-stroke mild cognitive impairment (psMCI). Participants will be individually randomized on enrollment using a random number generator to treatment with anodal tDCS + computerized cognitive treatment (CCT) versus sham + CCT (approximately 30 patients in each arm). Clinical evaluation including assessment of cognition will be performed pre- and post-intervention by individuals on the study team blinded to the participant's intervention. Participants will also undergo functional neuroimaging with magnetoencephalography (MEG) pre- and post-intervention (1, 3, and 6 months post-stroke to evaluate for initial and longer-term effects of treatment on cerebral ac |
| Who can participate | Inclusion Criteria: 1. Adults (≥18 years) presenting with neurological symptoms due to acute ischemic stroke (symptom onset within the week prior to admission). 2. Evidence on brain MRI of acute ischemic stroke (imaging negative strokes and TIAs will be excluded). 3. Native English speaker (by self-report) prior to stroke. 4. NIHSS \<8 at initial follow-up visit (approximately 30 days post-stroke). 5. mRS 0-2 at initial follow-up visit. Exclusion Criteria: 1. Primary intracerebral hemorrhage- as evidenced by blood on head CT or MRI. 2. Presence of proximal large vessel occlusion. 3. Cortical exam findings including aphasia or neglect. 4. Prior report or history of dementia or undertreated psychiatric illness. 5. Uncorrected hearing or visual loss. 6. Inability to attend treatment or follow |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Lead sponsor | Johns Hopkins University |
| Locations | Baltimore, Maryland, United States |
| Start date | 2022-09-01 |
| NCT ID | NCT05195398 |
| Official listing | https://clinicaltrials.gov/study/NCT05195398 |